New hope for transplant patients as cancer returns? early trial tests Immune-Boosting shot
NCT ID NCT06492707
Summary
This early-stage study is testing a new drug called DR-18 for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer has come back or persisted after a stem cell transplant. The main goals are to find a safe dose and see what side effects it causes. DR-18 is designed to boost the body's immune system to help fight the cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.